acute migraine attack. Migraine
Conditions
Interventions
Intervention 1: Intervention group: Ketorolac will be injected intravenously as a single 30 mg dose. Intervention 2: Intervention group: morphine will be injected intravenously as a single 5 mg dose.
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: being at least 18 years old having a migraine history for at least 1 year having 2 -10 migraine attacks per month if the patient is receiving a prophylactic medication, they shouldn't have changed or interrupted it at least for the previous 3 months
Exclusion criteria
Exclusion criteria: The patient is allergic to the studied drugs Contraindications to the use of these drugs such as basilar migraine(migraine with brainstem aura) and hemiplegic migraine, cerebrovascular and cardiovascular diseases, uncontrolled hypertension, ergotamine-containing drugs and monoamine oxidase inhibitors Blood dyscrasias Chronic painful diseases other than migraine Chronic hepatic, renal, and pulmonary failure Drug addiction Pregnancy Type 1 and 2 diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The effect of medication on reducing pain intensity based on visual analog scale (VAS) questionnaire. Timepoint: 0 minutes- 60 minutes -120 minutes. Method of measurement: Ten-point VAS questionnaire based on pain intensity. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects of headache on a person's quality of life and daily activities, and a score above 50 is nominated as a candidate for migraine. Timepoint: 0 minutes- 60 minutes -120 minutes. Method of measurement: A standard questionnaire to assess demographic characteristics and headache, including disability (test [HIT] -6). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMostafa Chenari
Oroumia University of Medical Sciences
Outcome results
None listed